Anti-CD45 Monoclonal Antibody, Alemtuzumab, and Fludarabine Followed By Donor Stem Cell Transplant in Treating Children With Severe Combined Immunodeficiency Disease or Other Primary Immunodeficiency Disorder - Related Studies

Anti-CD45 Monoclonal Antibody, Alemtuzumab, and Fludarabine Followed By Donor Stem Cell Transplant in Treating Children With Severe Combined Immunodeficiency Disease or Other Primary Immunodeficiency Disorder

This study is currently recruiting participants.

Study NCT00609258. Last updated on October 8, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Precancerous/Nonmalignant Condition

2	Additional conditions recognized in this trial
		Immunologic Deficiency Syndromes
		Precancerous Conditions
		Severe Combined Immunodeficiency

3	More general conditions related to this trial
		DNA Repair-Deficiency Disorders
		Immune System Diseases
		Infant, Newborn, Diseases
		Metabolic Diseases
		Neoplasms

4	Interventions listed in this trial
		alemtuzumab
		anti-CD45 monoclonal antibody
		fludarabine phosphate

5	Additional drug interventions recognized in this trial
		Antibodies
		Antibodies, Monoclonal
		Fludarabine
		Fludarabine monophosphate

6	More general drug interventions related to this trial
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Baylor College of Medicine